Approximate confidence limit for the reference scaled bioequivalence with a parallel design

The reference scaled bioequivalence has been proposed with many successful applications for the highly variable products. The statistical properties for the reference scaled bioequivalence have been studied for the commonly used crossover design. However, a crossover design may not be feasible in a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biopharmaceutical statistics 2020-03, Vol.30 (2), p.231-243
Main Authors: Liao, Jason J.Z., Li, Yifang
Format: Article
Language:English
Subjects:
Linearized criterion
parallel design
reference scaled bioequivalence
upper limit
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The reference scaled bioequivalence has been proposed with many successful applications for the highly variable products. The statistical properties for the reference scaled bioequivalence have been studied for the commonly used crossover design. However, a crossover design may not be feasible in a real application such as the biosimilar study, instead a parallel design is a more timely and cost-effective choice. In this paper, the approximate upper confidence interval limit for the linearized criteria in the reference scaled bioequivalence from a parallel design is derived. The performance of the approximation is evaluated through the simulation. The simulation results show that this approximation performs well and gives reasonable power and well-controlled type I error.
ISSN:1054-3406
1520-5711
DOI:10.1080/10543406.2019.1657438